GenAI models demonstrate high accuracy and consistency in pathological grading and risk assessment for lung adenocarcinoma.
Key Details
- 1Study tested GPT-4o, Claude-3.5-Sonnet, and Gemini-1.5-Pro on 492 digitized slides from public and independent sources.
- 2Claude-3.5-Sonnet achieved 82.3% accuracy in lung adenocarcinoma grading, with strong repeatability.
- 3Models extracted 11 histological features and 4 clinical variables for comprehensive risk assessment.
- 4Diagnostic and prognostic tasks were completed in minutes, much faster than human experts.
- 5AI models reduced inter-observer variability and enabled objective, standardized analysis across multiple samples.
- 6GenAI models surfaced new significant prognostic factors including interstitial fibrosis and papillary patterns.
Why It Matters
This breakthrough underscores the transformative potential of generative AI in digital pathology, promising faster, standardized, and potentially more insightful cancer diagnosis and prognosis translation. Such advances could boost accuracy in resource-limited settings and improve reproducibility in pathological assessments, reshaping clinical workflows.
Source
EurekAlert
Related News
•EurekAlert
NIH Invests Additional $12.6M in USC-Led Imaging AI for Alzheimer's
NIH has renewed and expanded its support for a USC-led consortium developing AI to decode and treat Alzheimer's using imaging and genomic data.
•EurekAlert
USC Unveils Joint Biomedical Engineering Department Bridging Medicine, Engineering, and Imaging
USC's medical and engineering schools launch a joint biomedical engineering department to accelerate interdisciplinary research and innovation, including imaging and AI.
•EurekAlert
AI Predicts Risks for Outpatient Stem Cell Therapy in Myeloma
Researchers use machine learning to predict adverse events during stem cell therapy for multiple myeloma, improving outpatient safety.